Daily Links 9/14/2011: NBCU sees big retrans fees; Double-edged issue for Comcast

SAP pleads guilty, will pay fine of $20 million in Oracle copyright case (San Jose Mercury News)

Qlik shares slide after Morgan Stanley cuts rating (AP via CBS MoneyWatch)

NBCUniversal's Steve Burke anticipates big bucks in retrans fees (LA Times: Company Town)

NBC could be next to lock down TV content online (Gigaom)

Time Warner Cable Net Customer Additions Stronger Than Expected, CEO Says (Bloomberg)

Philly newspapers cuts about 20 jobs; cite ad drop (AP via CanadianBusiness.com)

Sound Familiar? Philadelphia Newspapers Subsidize A Tablet To Sell You A Subscription (Wired: Epicenter)

Google Didn't Want All of Motorola Mobility (Light Reading Cable)

Motorola CEO Jha Getting $66M in Google Deal (AP via ABC News)
President and Motorola Home head Daniel Moloney will get $15.7 million when deal closes.

SAP Former Unit ‘Expected’ to Plead Guilty Today to Oracle Downloads (Bloomberg)

McKool Smith Secures $391 Million Judgment for Versata (PR Newswire)
Does this mean the judgement against SAP is final?

Apacheta Introduces Software-as-a-Service Offering for Direct-Store-Delivery, Merchandising, Transportation, Field Service (Business Wire)

OpenDesks Launches Interactive Map for Finding and Booking Workspace
OpenDesks Positions Itself as Go-To Workspace Solution
(Business Wire)

Philly-based Education investor Renovus closes $100m debut fund (AltAssets)


A natural fit: ImpactRX acquires TargetRX

ImpactRX of Mount Laurel has acquired TargetRX of Horsham, combining two companies that provide information to help Pharma companies better understand physicians' perscribing behavior. Terms were not disclosed. The new company will be known as ImpactRX.

Symphony Technology Group acquired a majority stake in ImpactRX in April (Merck Capital Ventures retains a minority stake). Late last month, ImpactRX appointed Gregory Ellis, who had been a Senior Partner with Rosetta Marketing, as President & CEO. TargetRX, founded in 1999, had raised at least $37 million; investors have included New Enterprise Asociates, Domain Associates, and Quaker BioVentures.

Press Release:

ImpactRx Acquires TargetRx

- Combined company to provide unparalleled insight into biopharma's sales and marketing effectiveness -

MOUNT LAUREL, N.J., Sept. 13, 2011 - ImpactRx, a Symphony Technology Group (STG) company and the pioneer in measuring the impact of promotion on physician prescribing behavior, announced today that it has acquired 100% of TargetRx, Inc., a leading provider of insight into the drivers of physician behavior for pharmaceutical companies, in order to combine the highly complementary capabilities of the two companies into a stronger solution offering for customers. The new company will be known as ImpactRx and new ImpactRx President and CEO, Gregory Ellis, will lead the combined company. Financial terms of the transaction were not disclosed.
"We are very excited to join forces with TargetRx," declared Ellis. "In the years we spent in the marketplace together, and from the feedback we received from customers, it's clear that the capabilities of these two companies are very complementary," Ellis stated. "ImpactRx specializes in helping clients understand the actual behavior of physicians in response to promotion, while TargetRx helps clients understand the underlying drivers of that behavior as they relate to physicians' attitudes, perceptions and beliefs," said Ellis. "Together, we will provide our clients with an unprecedented level of insight into what physicians do and why they do it," Ellis concluded.
Since its founding in 1999, TargetRx has served a majority of the top thirty pharmaceutical and biotech companies providing them insight into the drivers of product choice and the adoption of their brands. Powered by its unique AdvantageBuilder™ normative database and validated predictive models, TargetRx has developed proprietary analytical methodologies to provide clients critical insight into launch forecasting and positioning, physician segmentation and targeting for personal and non-personal promotion, professional marketing and message optimization, and sales and marketing execution and effectiveness.
"When we acquired ImpactRx earlier this year, our strategic intent was to build a differentiated solutions company in life sciences capable of delivering compelling value to clients through insights informed by data," said J.T. Treadwell, Managing Director with STG. "STG has a strong history of partnering with our companies to deliver innovation and growth, and we believe the addition of the TargetRx capabilities allows us to combine unique assets and complementary approaches, analytical talent, and a strong history of joint innovation as the foundation of a world-class solutions provider," Treadwell stated.
About ImpactRx
ImpactRx is the leading provider of consultative and analytically-based promotional effectiveness solutions to the healthcare industry. Powered by the ImpactData™ generated by its longitudinal panels of more than 4,000 targeted, iPhone-connected physicians (who through its proprietary technology are the exclusive source of continuously-captured promotion and treatment data) and combined with its industry-leading analytics and custom research capabilities, ImpactRx provides clients with unprecedented insight into the drivers of physician brand choice within a complete competitive context. These insights enable clients to improve brand performance by making more effective decisions around marketing strategy, field and channel execution and pre-launch and launch planning. ImpactRx is a Symphony Technology Group company. For more information, visit: www.impactrx.com.
About Symphony Technology Group
Symphony Technology Group (STG) is a strategic private equity firm with the mission of investing in and building great software and services companies. In addition to capital, STG provides transformation expertise to enable its portfolio companies to deliver maximum value to clients, to retain and attract the best talent, to drive growth through innovation, and to achieve best-in-class business performance. STG's current portfolio consists of fourteen global companies with combined revenue of $2.5 billion and 15,000 employees spread across North America, Europe and Asia. For more information, visit: www.symphonytg.com.


CSC acquires Philly/Hyderabad-based AppLabs

Tom Paine

The Indian press is reporting (with confirmation from the companies) that CSC has acquired AppLabs, the software testing business based in Philadelphia and Hyderabad, India, for a price some report to be in excess of $300 million.

CSC had been competing with Capgemini in recent days to acquire the company, according to reports.

AppLabs was founded in 2001 by Sashi Reddi, a serial entrepreneur who received his PHD from Wharton. It says it is ranked as the largest independent testing company in the world with 2,500 test professionals worldwide. A very small percentage of its employees are based in Philadelphia.

The deal represents an exit for private equity firm Westbridge Capital, which held a 50% stake in AppLabs, Reddi told the Indian press.